Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05FKE
|
||||
| Former ID |
DNC010254
|
||||
| Drug Name |
6-(piperazin-1-yl)-9-propyl-9H-purine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C12H18N6
|
||||
| Canonical SMILES |
CCCN1C=NC2=C1N=CN=C2N3CCNCC3
|
||||
| InChI |
1S/C12H18N6/c1-2-5-18-9-16-10-11(14-8-15-12(10)18)17-6-3-13-4-7-17/h8-9,13H,2-7H2,1H3
|
||||
| InChIKey |
BWJIAIMMFVYUQA-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 2C receptor | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Serotonergic synapse | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| PANTHER Pathway | 5HT2 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. Epub 2009 Oct 30.Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.